Search Results

You are looking at 61 - 70 of 362 items for :

  • "therapeutics" x
  • Refine by Access: All x
Clear All
Full access

NCCN Guidelines Updates: Management of Metastatic Colorectal Cancer

Wells A. Messersmith

Guidelines regarding BRAF . Abbreviation: mAb, monoclonal antibody. Disclosures: Dr. Messersmith has disclosed that he receives institutional grant/research support from Alexo Therapeutics, Inc.; D3 Pharma; Genentech, Inc.; Immunomedics; Incyte; Millennium

Full access

NCCN Guidelines: Pretransplant Recipient Evaluation and Management of Graft-Versus-Host Disease

Corey Cutler and Steven Z. Pavletic

clinical management have not changed, though they have become more complicated with the development and even FDA approval of new drugs for this indication. Similarly, use of HCT has shifted with the development of novel therapeutics in leukemia and lymphoma

Full access

Primary Androgen Deprivation Therapy for Nonmetastatic Prostate Cancer in Asia: Unique or Not?

Masaki Shiota

expectancy <10 years was challenged. This study has several limitations. First, the data on diagnosis, therapeutics, and outcome are very limited, and Gleason score, prostate-specific antigen level at diagnosis, detailed clinical stage and modality used for

Full access

Communicating Treatment Options to Older Patients: Challenges and Opportunities

Arti Hurria

of new therapeutics. Although oncology therapeutics undergo a stringent approval process under FDA regulations, older adults are inexplicably under-represented in registration trials. As of 1993, federal law has mandated that the NIH include and

Full access

Advances in the Care of Adult Patients With Acute Lymphoblastic Leukemia: Optimism Tempered by Reality

Joseph C. Alvarnas and Patrick A. Brown

new classes of antileukemia drugs and cellular therapeutics are fast becoming part of our ALL care strategy. These include therapeutics targeted at the expanding list of tumor-specific gene mutations and rearrangements that characterize the novel “Ph

Full access

How to Monitor Patients with Chronic Myelogenous Leukemia

Michael E O'Dwyer

The author participates in Speakers' Bureaus for Novartis Pharmaceuticals and Cell Therapeutics. References 1 Nowell PC Hungerford DA . A minute chromosome in human chronic granulocytic leukemia . Science 1960 ; 132 : 1497

Full access

Assuring Access to Academic Cancer Centers

Harold J. Burstein

through the NIH; to deny patients coverage for care at such facilities is to keep them away from programs that they built through financial support. It is also to deprive them of access to the emerging technologies and therapeutics that are reshaping

Full access

Open Notes Are Here: Are We Ready?

Margaret Tempero

Medicine and Director of the UCSF Pancreas Center and editor-in-chief of JNCCN . Her research career has focused on pancreatic ductal adenocarcinoma, especially in the area of investigational therapeutics. Dr. Tempero has served on the ASCO Board of

Full access

Point: Chemosensitivity Assays Have a Role in the Management of Recurrent Ovarian Cancer

Julian C. Schink and Larry J. Copeland

the use of assay-directed therapy is from studies of the ChemoFx assay (Precision Therapeutics, Pittsburgh, Pennsylvania). Gallion et al. 10 evaluated the value of this chemosensitivity assay test for predicting progression-free interval in 135 women

Full access

Together Again!

Margaret Tempero

Director of the UCSF Pancreas Center and editor-in-chief of JNCCN . Her research career has focused on pancreatic ductal adenocarcinoma, especially in the area of investigational therapeutics. Dr. Tempero has served on the ASCO Board of Directors and as